Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6682663 | 0.86 | PKM (0.47) | MAPTRXFP1TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL6678882 | 0.84 | ALDH1A1 (0.43) | MAPTRXFP1TP53ALDH1A1KDM4E | |
| SCHEMBL7118484 | 0.82 | MAPT (0.40) | MAPTRXFP1TP53ALDH1A1KDM4E | |
| SCHEMBL6677958 | 0.81 | SMN1; SMN2 (0.44) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6684214 | 0.75 | THRB (0.43) | MAPTRXFP1TP53ALDH1A1KDM4E | |
| SCHEMBL6257046 | 0.74 | THRB (0.47) | MAPTRXFP1TP53ALDH1A1KDM4E | |
| SCHEMBL6678368 | 0.73 | MEN1 (0.41) | MAPTRXFP1TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL6502433 | 0.72 | CXCR3 (0.46) | MAPTTP53SMN1; SMN2 | |
| SCHEMBL7119000 | 0.71 | MEN1 (0.40) | MAPTRXFP1TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL6678378 | 0.71 | PKM (0.50) | MAPTALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004014921-A1 | 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | MAPT 1473/4885RXFP1 451/4885TP53 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.